Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8537552 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL8536337 | 0.98 | TSHR (0.45) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL22848850 | 0.92 | MEN1 (0.43) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL22606455 | 0.92 | MEN1 (0.43) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL22606458 | 0.92 | MEN1 (0.43) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL24508454 | 0.92 | MEN1 (0.47) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL15888695 | 0.92 | ALDH1A1 (0.47) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL22802989 | 0.92 | MEN1 (0.43) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL22856422 | 0.92 | ALDH1A1 (0.47) | MEN1KMT2ATSHRSPRKDM4E | |
| SCHEMBL13341361 | 0.92 | MEN1 (0.43) | MEN1KMT2ATSHRSPRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070161577-A1 | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones | IRONWOOD PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161577-A1 | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones | IRONWOOD PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | MEN1 1671/4885KMT2A 1904/4885TSHR 3868/4885 |
| US-20070161577-A1 | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones | APOB, PCSK9, HDLBP | MEN1 2381/4885KMT2A 2068/4885TSHR 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.